Pfizer and ExonHit partnered to identify biomarkers for Alzheimer's disease using ExonHit's Genome-Wide SpliceArray technology

ExonHit S.A.

France / Small-Cap Biopharma (<$1 billion)

$47.4m on 10/14/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Pfizer Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced